Andrew Ambrosy to Vasopressins
This is a "connection" page, showing publications Andrew Ambrosy has written about Vasopressins.
Connection Strength
0.139
-
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
Score: 0.111
-
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2012 Nov; 5(6):750-8.
Score: 0.027